ClinicalTrials.gg
CompletedNCT01201265Updated May 27, 2016Results posted

A Study of Bevacizumab in Combination With Gemcitabine and Carboplatin in Participants With Triple Negative Metastatic Breast Cancer

A Phase 2 interventional study of Bevacizumab and Carboplatin in Breast Cancer, sponsored by Hoffmann-La Roche. Completed at 12 sites in India. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2016-05-27.

Sponsored by Hoffmann-La Roche · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
40
Allocation
Not applicable
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 131 studies testing bevacizumab in Breast Neoplasms — 9 open to participants now, 10 under way, none of them phase 3. Bevacizumab · Breast Neoplasms.

Enrollment
89th of 130
40 · median 58
Started
2011
with 2 others
Phase 2
89 of 131
6 open now
Registered
100th of 131
by date
Lead sponsor
14 of 131
Hoffmann-La Roche

Among the 131 studies testing bevacizumab in Breast Neoplasms, this one is the 89th largest by enrollment of the 130 interventional ones that give a count, is one of 3 that started in 2011, is one of 89 in phase 2, and was the 100th registered.

Breast Neoplasms

14,837 studies on the registry are indexed under Breast Neoplasms; 3,320 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

9 of the 131 studies testing bevacizumab in Breast Neoplasms are open now, in 12 countries. Recruiting first, the newest first:

4 more — sign in →

By country, each count listing its studies:

All 9 open studies →

About bevacizumab

Bevacizumab: first FDA approval 2004 (AVASTIN), first EMA approval 2005. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 2,399 Breast Neoplasms studies recruiting now, 1,570 (65%) set no upper age limit and 592 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 131 studies testing bevacizumab in Breast Neoplasms, or all of them as a file.
02

Study summary

This multicenter study will assess the efficacy and safety of bevacizumab in combination with gemcitabine and cisplatin as first line treatment in participants with triple negative metastatic breast cancer. Participants will receive bevacizumab at a dose of 15 mg/kg intravenously (iv) every 3 weeks, plus gemcitabine (1000 mg/m2 iv) and carboplatin (iv to an area under curve [AUC]=2) on Days 1 and 8 of each 3-week cycle. Anticipated time on study treatment is until disease progression.

03

Conditions studied

  • Breast Cancer

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Female participants, >/= 18 years of age
  • breast cancer
  • Estrogen receptor-, progesterone- and human epidermal growth factor receptor 2 ()-negative disease
  • Treatment-naïve for metastatic breast cancer
  • (ECOG) performance status 0-2
  • Adequate hematological, renal and liver function
  • Patients should have received Anthracyclines and Taxanes in the setting
  • Women of must agree to use adequate (per institutional standard of care) during treatment and until 6 months after the last administration of products

Exclusion criteria

Exclusion Criteria:

  • Prior treatment for breast cancer
  • Central nervous system (CNS) metastasis
  • Uncontrolled hypertension (> 170/95 mmHg)
  • Evidence of bleeding diathesis, coagulopathy or hemorrhage at baseline
  • Other within the last 5 years, except for adequately treated carcinoma in situ of the cervix or squamous carcinoma of the skin, or adequately controlled limited basal cell skin cancer.
  • Prior therapy with gemcitabine or carboplatin in the metastatic setting. Participants having received gemcitabine or carboplatin as part of therapy are eligible, if recurrence was first documented >6 months after the last exposure to the drug(s)
  • Requirement of chronic use of agents
  • , or infection
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
40 participants (actual)

Study arms

  • Experimental
    Overall Participants

    Participants received a combination therapy of bevacizumab with gemcitabine plus carboplatin.

    Drug: Bevacizumab · Drug: Carboplatin · Drug: Gemcitabine

Interventions

  • 15 mg/kg iv every 3 weeks

    Also known as: Avastin

  • to an AUC = 2, on days 1 and 8 of each 3-week cycle

  • 1000 mg/m2 iv on days 1 and 8 of each 3-week cycle

06

What researchers measure

Primary outcomes

  1. Progression-free Survival (PFS)

    Progression free survival (PFS) was calculated in days from the date of registration until the earliest date of documented disease progression or death. The median PFS time with 95% confidence interval (CI) was estimated using Kaplan Meier method. The progression-free survival was assessed utilizing computer tomography (CT)/ magnetic resonance imaging (MRI)/bone scans and X-ray and Response Evaluation Criteria in Solid Tumors (RECIST) v. 1.1. Progression of disease is defined as at least 20% increase in the sum of diameters of target lesions compared to the smallest sum of diameters on-study and absolute increase of at least 5 mm, progression of existing non-target lesions, or presence of new lesions.

    Time frame: From the date of registration until the disease progression or death (up to 1541 days).

Secondary outcomes

  1. Percentage of Participants Achieving an Overall Response

    The overall response rate (ORR) was defined as complete response (CR) + partial response (PR). ORR was summarized using number and percentage along with two-sided 95% Pearson-Clopper CI. The overall response rate was assessed utilizing the RECIST v. 1.1. CR: disappearance of all target and non-target lesions (TLs) and normalization of tumor markers. Pathological lymph nodes must have short axis measures less than (\<) 10 millimeter (mm). PR: at least a 30% decrease in the sum of measures (longest diameter for tumor lesions and short axis measure for nodes) of TLs, taking as reference the baseline sum of diameters.

    Time frame: From the date of registration until the disease progression or death (up to 1541 days)

  2. Percentage of Participants Achieving a Clinical Benefit Response (CBR)

    Clinical benefit response was defined as a complete response (CR), partial response (PR) or stable disease (SD). CBR was assessed using Recist v.1.1. CR: disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm. PR: At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. SD: neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum diameters while on study. PD: at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm.

    Time frame: From the date of registration until the disease progression or death (up to 1541 days)

  3. Time to Progression (TTP)

    Duration of time to progression (TTP) was estimated using the Kaplan-Meier method. The time to progression was calculated in days from the date of registration until the earliest date of documented disease progression.

    Time frame: From the date of registration until the disease progression (up to 1541 days).

  4. Overall Survival (OS)

    Overall survival was measured from the date of the first study drug dose to the date of death from any cause. The median overall survival time with 95%CI was estimated using Kaplan-Meier method.

    Time frame: From the date of registration until the disease progression or death (up to 1541 days)

  5. Number of Participants With an Adverse Event (AE)

    An AE was defined as any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product.

    Time frame: Up to 28 days after termination of study treatment (approximately 1569 days)

  6. Change From Baseline to Cycle 6 in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-30)

    The EORTC QLQ-C30 (version 3.0) questionnaire incorporates 9 multi scale items: 5 functional scales (physical, role, cognitive, emotional and social); 3 symptom scales (fatigue, pain and nausea \& vomiting); and a global health and quality-of-life scale. It contains 30 questions. The score for each item and the overall score ranges from 0 to 100. A high overall scale and subscale scores represent improved health status. However, in case of symptoms, higher scores suggest increased perception of these symptoms.

    Time frame: Baseline, cycle 6

  7. Change From Baseline in Systolic Blood Pressure (SBP)

    Change from baseline in SBP was analyzed by overall response (CR+PR, SD+PD).

    Time frame: Baseline, Cycle 6, 12 of treatment

  8. Change From Baseline in Diastolic Blood Pressure (DBP)

    Change from baseline in DBP was analyzed by overall response (CR+PR, SD+PD).

    Time frame: Baseline, Cycle 6, 12 of treatment

07

Results

Posted May 27, 2016

Participant flow

Participant flow — Overall Study
MilestoneAll Participants
Started40
Completed2
Not completed38
Withdrew: Death14
Withdrew: Insufficient therapeutic response3
Withdrew: Lost to follow-up10
Withdrew: Withdrawal by subject7
Withdrew: Disease progression4

Outcome measures

PrimaryProgression-free Survival (PFS)

Progression free survival (PFS) was calculated in days from the date of registration until the earliest date of documented disease progression or death. The median PFS time with 95% confidence interval (CI) was estimated using Kaplan Meier method. The progression-free survival was assessed utilizing computer tomography (CT)/ magnetic resonance imaging (MRI)/bone scans and X-ray and Response Evaluation Criteria in Solid Tumors (RECIST) v. 1.1. Progression of disease is defined as at least 20% increase in the sum of diameters of target lesions compared to the smallest sum of diameters on-study and absolute increase of at least 5 mm, progression of existing non-target lesions, or presence of new lesions.

Time frame:
From the date of registration until the disease progression or death (up to 1541 days).
Reported as:
Median · days
Progression-free Survival (PFS)
daysAll Participants
Progression-free Survival (PFS)255 (157 to 465)
SecondaryPercentage of Participants Achieving an Overall Response

The overall response rate (ORR) was defined as complete response (CR) + partial response (PR). ORR was summarized using number and percentage along with two-sided 95% Pearson-Clopper CI. The overall response rate was assessed utilizing the RECIST v. 1.1. CR: disappearance of all target and non-target lesions (TLs) and normalization of tumor markers. Pathological lymph nodes must have short axis measures less than (\<) 10 millimeter (mm). PR: at least a 30% decrease in the sum of measures (longest diameter for tumor lesions and short axis measure for nodes) of TLs, taking as reference the baseline sum of diameters.

Time frame:
From the date of registration until the disease progression or death (up to 1541 days)
Reported as:
Number · percentage of participants
Percentage of Participants Achieving an Overall Response
percentage of participantsAll Participants
Percentage of Participants Achieving an Overall Response50.0 (33.8 to 66.2)
SecondaryPercentage of Participants Achieving a Clinical Benefit Response (CBR)

Clinical benefit response was defined as a complete response (CR), partial response (PR) or stable disease (SD). CBR was assessed using Recist v.1.1. CR: disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm. PR: At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. SD: neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum diameters while on study. PD: at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm.

Time frame:
From the date of registration until the disease progression or death (up to 1541 days)
Reported as:
Number · percentage of participants
Percentage of Participants Achieving a Clinical Benefit Response (CBR)
percentage of participantsAll Participants
Percentage of Participants Achieving a Clinical Benefit Response (CBR)92.5 (79.6 to 98.4)
SecondaryTime to Progression (TTP)

Duration of time to progression (TTP) was estimated using the Kaplan-Meier method. The time to progression was calculated in days from the date of registration until the earliest date of documented disease progression.

Time frame:
From the date of registration until the disease progression (up to 1541 days).
Reported as:
Median · days
Time to Progression (TTP)
daysAll Participants
Time to Progression (TTP)269.0 (182.0 to 551.0)
SecondaryOverall Survival (OS)

Overall survival was measured from the date of the first study drug dose to the date of death from any cause. The median overall survival time with 95%CI was estimated using Kaplan-Meier method.

Time frame:
From the date of registration until the disease progression or death (up to 1541 days)
Reported as:
Median · days
Overall Survival (OS)
daysAll Participants
Overall Survival (OS)475.0 (358.0 to 759.0)
SecondaryNumber of Participants With an Adverse Event (AE)

An AE was defined as any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product.

Time frame:
Up to 28 days after termination of study treatment (approximately 1569 days)
Reported as:
Number · participants
Number of Participants With an Adverse Event (AE)
participantsAll Participants
Number of Participants With an Adverse Event (AE)24
SecondaryChange From Baseline to Cycle 6 in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-30)

The EORTC QLQ-C30 (version 3.0) questionnaire incorporates 9 multi scale items: 5 functional scales (physical, role, cognitive, emotional and social); 3 symptom scales (fatigue, pain and nausea \& vomiting); and a global health and quality-of-life scale. It contains 30 questions. The score for each item and the overall score ranges from 0 to 100. A high overall scale and subscale scores represent improved health status. However, in case of symptoms, higher scores suggest increased perception of these symptoms.

Time frame:
Baseline, cycle 6
Reported as:
Mean · units on a scale
Change From Baseline to Cycle 6 in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-30)
units on a scaleAll Participants
Baseline; physical (n=40)69.33 ± 20.963
Change at Cycle 6; physical (n=28)-8.82 ± 24.154
Baseline; role (n=40)71.26 ± 25.311
Change at Cycle 6; role (n=28)-5.36 ± 22.705
Baseline; cognitive (n=40)74.58 ± 24.745
Change at Cycle 6; cognitive (n=28)-4.17 ± 27.444
Baseline; emotional (n=40)61.87 ± 22.396
Change at Cycle 6; emotional (n=28)-15.78 ± 23.929
Baseline; social (n=40)65.42 ± 29.330
Change at Cycle 6; social (n=28)-8.33 ± 27.026
Baseline; fatigue (n=40)42.21 ± 20.026
Change at Cycle 6; fatigue (n=28)8.35 ± 25.785
Baseline; pain (n=40)34.58 ± 25.428
Change at Cycle 6; pain (n=28)13.09 ± 33.744
Baseline; nausea and vomiting (n=40)16.67 ± 20.326
Change at Cycle 6; nausea and vomiting (n=28)2.38 ± 19.082
Baseline; global health & QOL (n=40)58.55 ± 17.750
Change at Cycle 6; global health & QOL (n=28)-3.86 ± 17.191
SecondaryChange From Baseline in Systolic Blood Pressure (SBP)

Change from baseline in SBP was analyzed by overall response (CR+PR, SD+PD).

Time frame:
Baseline, Cycle 6, 12 of treatment
Reported as:
Mean · millimetre of mercury (mmHg)
Change From Baseline in Systolic Blood Pressure (SBP)
millimetre of mercury (mmHg)All Participants
Baseline; CR+PR (n= 19)124.8 ± 12.86
Change at cycle 6; CR+PR (n=14)-4.6 ± 12.16
Change at cycle 12; CR+PR at cycle 12 (n=5)-4.0 ± 18.17
Baseline; SD+PD (n= 18)123.6 ± 6.82
Change at cycle 6; SD+PD at cycle 6 (n=13)0.2 ± 12.68
Change at cycle 12; SD+PD at cycle 12 (n=4)-6.3 ± 17.97
SecondaryChange From Baseline in Diastolic Blood Pressure (DBP)

Change from baseline in DBP was analyzed by overall response (CR+PR, SD+PD).

Time frame:
Baseline, Cycle 6, 12 of treatment
Reported as:
Mean · mmHg
Change From Baseline in Diastolic Blood Pressure (DBP)
mmHgAll Participants
Baseline; CR+PR (n= 19)80.4 ± 9.65
Change at cycle 6; CR+PR (n=14)-4.1 ± 10.83
Change at cycle 12; CR+PR (n=5)-2.0 ± 14.83
Baseline; SD+PD (n= 18)78.9 ± 7.58
Change at cycle 6; SD+PD (n=13)2.3 ± 10.92
Change at cycle 12; SD+PD (n=4)7.5 ± 12.58

Adverse events

Collected over Up to 28 days after termination of study treatment (approximately 1569 days). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
All Particiapants—17/40 (42.5%)18/40 (45%)
Most frequent serious events
Showing 10 of 18
Most frequent serious events
EventAll Particiapants
Disease ProgressionGeneral disorders6/40
ThrombocytopeniaBlood and lymphatic system disorders5/40
Febrile NeutropeniaBlood and lymphatic system disorders3/40
PyrexiaGeneral disorders3/40
AnaemiaBlood and lymphatic system disorders2/40
NeutropeniaBlood and lymphatic system disorders2/40
Pleural EffusionRespiratory, thoracic and mediastinal disorders2/40
Pericardial EffusionCardiac disorders1/40
Abdominal Pain LowerGastrointestinal disorders1/40
FatigueGeneral disorders1/40
Most frequent other events
Most frequent other events
EventAll Particiapants
NeutropeniaBlood and lymphatic system disorders10/40
ThrombocytopeniaBlood and lymphatic system disorders9/40
AnaemiaBlood and lymphatic system disorders5/40
LeukopeniaBlood and lymphatic system disorders3/40
Disease ProgressionGeneral disorders3/40
Febrile NeutropeniaBlood and lymphatic system disorders2/40
StomatitisGastrointestinal disorders2/40

Baseline characteristics

Age, Continuous
Age, Continuous(years)All Participants
Mean47.5 ± 10.68
Sex: Female, Male
Sex: Female, Male(Participants)All Participants
Female40
Male0
08

Study locations

12 sites
  • Ahmedabad, 380009, India
  • Bangalore, 560029, India
  • Bangalore, 560054, India
  • Delhi, 110029, India
  • Gandhinagar, 382428, India
  • Mumbai, 400012, India
  • Mumbai, 400016, India
  • Mumbai, 400020, India
  • New Delhi, 110011, India
  • New Delhi, 110085, India
  • Pune, 411004, India
  • Vellore, 632004, India
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Feb 2011, a primary completion of Apr 2015 and a completion of Apr 2015. It does not say whether these dates are actual or estimated.

Results were first posted in May 2016, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 6, 2010
First posted
Sep 14, 2010
Start
Feb 2011
Primary completionActual
Apr 2015
CompletionActual
Apr 2015
Results first posted
May 27, 2016
Last update
May 27, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 27, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01201265
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
Sep 14, 2010
Start date
Feb 2011
Primary completion
Apr 2015
Completion
Apr 2015
Results posted
May 27, 2016
Last update
May 27, 2016

Study contacts

Clinical Trials
study director · Hoffmann-La Roche

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Bevacizumab · Carboplatin · Gemcitabine

Start the discussion